1. Two peptide medicines most readers have never heard of
Peptide Data's compound library is dominated by research reagents — the BPC-157s and TB-500s of the grey market. It is worth pausing on the opposite end of the spectrum: peptides that have been through full UK marketing authorisation and are used routinely in NHS cardiac catheter laboratories. Bivalirudin and eptifibatide are both short synthetic peptides, both given intravenously by clinicians rather than self-administered, and both licensed in the UK as prescription-only medicines (POM) under the Human Medicines Regulations 2012. They illustrate how far peptide pharmacology can travel from the research-reagent market, and why 'it is a peptide' tells you nothing about legal status or evidence grade.
2. Bivalirudin: a hirudin analogue and bivalent direct thrombin inhibitor
Bivalirudin is a 20-amino-acid synthetic analogue of hirudin, the anticoagulant protein found in the saliva of the medicinal leech (Hirudo medicinalis). It is a direct thrombin inhibitor. Unlike heparin, which works indirectly by potentiating antithrombin, bivalirudin binds thrombin itself. Its action is bivalent: one region engages thrombin's catalytic active site, the other its exosite 1 (the fibrinogen-binding site). That bivalent binding is why it inhibits both circulating and clot-bound thrombin.
A structural feature worth noting is that bivalirudin's N-terminal region is cleaved slowly by thrombin itself, so the drug is progressively metabolised by its own target. This contributes to its short duration of action and its relatively predictable, dose-proportional anticoagulant effect. It prolongs the activated clotting time (ACT), the activated partial thromboplastin time (aPTT) and the thrombin time.
The pivotal evidence sits in percutaneous coronary intervention (PCI). REPLACE-2 (JAMA, 2003) compared bivalirudin with provisional glycoprotein IIb/IIIa blockade against heparin with planned GPIIb/IIIa blockade, and reported broadly comparable ischaemic outcomes with less bleeding in the bivalirudin arm. HORIZONS-AMI (NEJM, 2008) extended the comparison to primary PCI in acute myocardial infarction, where bivalirudin reduced bleeding and, in that trial, 30-day mortality — a finding that later analyses and subsequent trials have made more nuanced. The UK-authorised indication is narrower than the trial literature: bivalirudin is licensed as an anticoagulant for patients undergoing PCI, including those with heparin-induced thrombocytopenia (HIT).
3. Eptifibatide: a disintegrin-derived GPIIb/IIIa antagonist
Eptifibatide is a cyclic heptapeptide derived from barbourin, a disintegrin found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Where bivalirudin targets thrombin, eptifibatide targets the platelet: it is a glycoprotein IIb/IIIa (integrin alphaIIbbeta3) antagonist. That receptor is the final common pathway of platelet aggregation, so blocking it prevents fibrinogen-mediated platelet cross-linking regardless of which upstream agonist — thrombin, ADP or collagen — started the process.
Eptifibatide's pharmacophore is the KGD (Lys-Gly-Asp) sequence; barbourin's native motif was engineered into a cyclic structure with higher affinity and a longer half-life. It is given as a bolus followed by a continuous infusion and is cleared partly by the kidney.
The key trials are PURSUIT (NEJM, 1998), in acute coronary syndromes without persistent ST elevation, and ESPRIT (Lancet, 2000), in planned coronary stenting using a higher-dose regimen. Both showed reductions in the composite ischaemic endpoint, at the cost of increased bleeding, particularly in patients also receiving heparin. Eptifibatide's use has declined since the routine adoption of potent oral P2Y12 inhibitors and radial-access PCI, but it remains in UK formularies for selected high-risk cases, and Tonin and colleagues (Int J Mol Sci, 2023) have reviewed emerging non-cardiac applications.
4. Why these two are a useful contrast
Read side by side, bivalirudin and eptifibatide make a pair of teaching points.
First, peptide medicines are not a single pharmacological class. A short linear peptide that inhibits an enzyme (bivalirudin) and a cyclic peptide that blocks an integrin (eptifibatide) share only their size and their route of administration. Peptide identity is a chemistry fact, not a mechanism.
Second, both demonstrate that peptide drugs can carry robust, randomised human evidence. That is the standard against which the research-reagent market should be judged — and generally is not. BPC-157's nearly empty human column and these agents' thousands of randomised patients are not morally different molecules; they are products of different development paths.
Third, both illustrate the ordinary UK regulatory route. Neither is a 'legal grey area': each holds a UK marketing authorisation as a POM, is supplied to hospitals, and sits outside the research-reagent channel entirely.
5. UK legal and regulatory framing
Bivalirudin and eptifibatide are prescription-only medicines under the Human Medicines Regulations 2012, which implement the framework of the Medicines Act 1968. They may be supplied only against a prescription from an appropriate practitioner and are used in secondary care. They are not lawful to purchase as 'research chemicals' for personal use, and no UK marketing authorisation covers self-administration.
The boundary that matters for this site's readers is the same one that runs through every other page: a compound's status as a peptide has no bearing on whether it is a licensed medicine, a controlled drug, or a research reagent sold under a 'research use only' label. MHRA-authorised products such as these are regulated medicines; the grey-market peptides in the library are not. Nothing here is consumption advice, and Peptide Data does not endorse the use of any compound outside its authorised indication and a clinician's supervision.
6. Evidence grading at a glance
Applying Peptide Data's four-tier system to the licensed indications, both bivalirudin and eptifibatide sit at Strong evidence: multiple randomised controlled trials, formal regulatory assessment, and a meta-analytic literature. That grade applies to the licensed, clinician-administered cardiac indications. It does not transfer to any off-label or non-cardiac use, where the human dataset may be sparse or absent.
7. The bottom line
Bivalirudin and eptifibatide are peptide medicines in the ordinary sense: synthetic, evidence-graded, UK-licensed, and prescribed by specialists rather than sold for personal use. They are worth knowing about because they set the evidentiary ceiling for the peptide field, and because they show how misleading the single word 'peptide' can be as a guide to what a substance is, how strong its evidence is, or how the law treats it.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.